iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.00M | 35.00M | 35.00M | 0.00 | 12.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.00M | 35.00M | 35.00M | 0.00 | 12.60M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 35.00M | 35.00M | 35.00M | 0.00 | 12.60M |
| SG&A Expenses | 49.08M | 49.64M | 50.17M | 51.15M | 50.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 191.81M | 181.09M | 175.33M | 169.29M | 160.05M |
| Operating Income | -156.81M | -146.09M | -140.33M | -169.29M | -147.45M |
| Income Before Tax | -120.34M | -112.17M | -102.48M | -130.68M | -109.03M |
| Income Tax Expenses | 14.07M | 9.08M | 5.66M | 4.63M | 3.61M |
| Earnings from Continuing Operations | -134.41 | -121.25 | -108.14 | -135.31 | -112.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.41M | -121.25M | -108.14M | -135.31M | -112.64M |
| EBIT | -156.81M | -146.09M | -140.33M | -169.29M | -147.45M |
| EBITDA | -155.57M | -144.95M | -139.27M | -168.31M | -146.55M |
| EPS Basic | -3.31 | -3.15 | -3.00 | -3.78 | -3.15 |
| Normalized Basic EPS | -1.86 | -1.82 | -1.78 | -2.28 | -1.91 |
| EPS Diluted | -3.31 | -3.16 | -3.00 | -3.78 | -3.15 |
| Normalized Diluted EPS | -1.86 | -1.82 | -1.78 | -2.28 | -1.91 |
| Average Basic Shares Outstanding | 161.86M | 154.46M | 147.11M | 143.18M | 143.05M |
| Average Diluted Shares Outstanding | 161.86M | 154.46M | 147.11M | 143.18M | 143.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
